Journal of Pharmacovigilance

Minoxidil induced hypertrichosis in children

4^th International Conference and Exhibition on Pharmacovigilance & Clinical Trials

August 10-12, 2015 London, UK

N Guerouaz, K Senouci, M Ait Ourharoui and B Hassam

Posters-Accepted Abstracts: J Pharmacovigilance

Abstract:

Introduction: Minoxidil is a strong arterial vasodilator used in the treatment of hypertension. In dermatology, topic minoxidil is widely used to treat hair fall. Hypertrichosis may occur if this form is misused. Case report: A 5 year-old girl developed patchy alopecia areata of the scalp. She was treated by minoxidil 2% lotion. Parents did not observe medical prescription and applied treatment hazardously over 10 times a day. Regrowth of hair was rapidly obtained. However, the parents complained of extensive hypertrichosis covering the front and the back. Physical examination revealed no hypotension and hirsutism evaluated at 20/36 on the Ferriman and Gallwey scale. Serum levels of 17 hydroxyprogesterone, 17 alfa progesterone, testosterone and cotisol were within normal ranges excluding hormonal disorder. Discontinuation of minoxidil was followed by progressive regression of hypertrichosis. Discussion: Systemic effects are rarely reported with minoxidil based lotions. Indeed, transcutaneous absorption is insignificant ranging from 0. 3 to 4.5%. The main systemic side effects include hypotension, tachycardia and ECG changes. Hypertrichosis to topical minoxidil solution has been reported more frequently in females than in males. This side effect is dose-related and is mainly localized in the face. Discontinuation of treatment makes this trouble reversible. However medical supervision must be considered for a long time because of the product?s very long action. Conclusion: Minoxidil is the best accompanying treatment of alopecia areata. It must be delivered on medical prescription to ensure the best results and the maximum security use especially in children and women.